There is currently no FDA-approved treatment for RYR1- related myopathies (RYR1-RM), although it is worth noting the RYR1 antagonist, dantrolene, is approved for use during MH events to attenuate excessive ER/SR calcium release [20]. The gene discussed is RYR1; the disease is myopathy.